Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: biostruggle who wrote (3103)	8/21/2002 5:16:20 PM
From: dalroi	Respond to of 10345

Marvin Any idea how big those royalties are ? cheers S

To: biostruggle who wrote (3103)	8/21/2002 5:43:26 PM
From: Qualified Opinion	Read Replies (1) \| Respond to of 10345

FDA Grants Marketing Clearance For Ritalin(R) LA, A Once-Daily Formulation of Ritalin(R) For ADHD That Lasts Through The Entire School Day Video Available Soon At: prnewswire.com NEW YORK, Aug. 21 /PRNewswire/ -- ADHD is the most studied childhood psychiatric disorder and it can have a profound impact on children and their families. Because of the severity and pervasiveness of the symptoms, ADHD can cause problems academically, socially and psychologically, affecting a child's self-esteem and ability to reach his/her full potential. Today, Novartis Pharmaceuticals Corporation announced that the U.S. Food and Drug Administration (FDA) has granted marketing clearance for Ritalin® LA (methylphenidate HCl) extended-release capsules, a new once-daily formulation of Ritalin® (methylphenidate HCl) that eliminates the need for a mid-day dose during school. The "LA" stands for long acting", which means that the medication only needs to be taken once in the morning. This video news release profiles a child who is being treated for ADHD and features an interview with a Harvard psychiatrist and animation of how medicine for ADHD works. SOUNDBITES: * Thomas Spencer, M.D., Associate Professor of Psychiatry, Harvard Medical School and Assistant Director of the Pediatric Psychopharmacology Research Program at Massachusetts General Hospital. * Jonathan Adler, 7 yr. old with ADHD. Video Provided By: Novartis Pharmaceuticals Corporation FOR TECHNICAL INFORMATION OR HARD COPY REQUESTS PLEASE CALL: Maria McCarthy at: 212-375-0021 SOURCE: Novartis Pharmaceuticals Corporation Link:http://biz.yahoo.com/prnews/020821/nyw021_1.html